UK Diabetes Drugs Market Analysis

UK Diabetes Drugs Market Analysis


$ 3999

The UK diabetes drugs market size was valued at $1.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030 and will reach $2.21 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The UK diabetes drug market will grow because UK has a strong pharmaceutical industry with several established companies and emerging biotech companies developing new diabetes drugs. The key market players are AstraZeneca, GlaxoSmithKline, Eli Lilly and Company, Novo Nordisk, Sanofi, and others.

ID: IN10GBPH009 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Chandani Patel

Buy Now

UK Diabetes Drugs Market Executive Summary

The UK diabetes drugs market size was valued at $1.6 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030 and will reach $2.21 Bn in 2030. According to the World Bank, the United Kingdom had a Gross Domestic Product (GDP) of $2.63 trillion in 2020. In terms of health expenditure, the UK spent 9.8% of its GDP on healthcare in 2019, according to data from the Organisation for Economic Co-operation and Development (OECD). Compared to other high-income countries, the UK's health expenditure as a share of GDP is slightly below the OECD average of 10.3%. However, the UK has a publicly funded National Health Service (NHS) that provides free or low-cost healthcare to all UK residents, which makes the UK's healthcare system unique among high-income countries.

Diabetes is a significant health issue in the UK, affecting an estimated 3.9 Mn people, or about 6% of the population. The prevalence of diabetes in the UK is expected to continue to increase due to factors such as an aging population, changing lifestyles, and rising obesity rates. The increasing prevalence of diabetes in the UK has a significant impact on the diabetes drugs market. With more people being diagnosed with diabetes, there is a growing demand for diabetes drugs to help manage the disease. This has led to a growing market for diabetes drugs in the UK, with both established pharmaceutical companies and emerging biotech companies developing new treatments to address this demand.

At the same time, the UK government's cost-containment measures, including the use of cost-effectiveness assessments by NICE, have also had an impact on the diabetes drugs market. While these measures have helped to ensure that the NHS provides cost-effective treatments, they have also limited the availability of some newer, more expensive diabetes drugs, which may be less cost-effective in the short term but may offer significant benefits in the long term.

Overall, the diabetes drugs market in the UK is driven by both the growing demand for diabetes treatments and the need to balance cost-effectiveness with the need for innovation and patient access to new and effective therapies. As the prevalence of diabetes in the UK continues to increase, it is likely that the demand for diabetes drugs will also continue to grow new opportunities in the market.

uk diabetes drugs market

Market Dynamics

Market Growth Drivers Analysis

Increasing prevalence of diabetes: Diabetes is a significant health issue in the UK, affecting an estimated 3.9 Mn people. With the prevalence of diabetes expected to continue to rise, there is a growing demand for diabetes drugs to manage the disease.

A growing pipeline of innovative drugs: The UK has a strong pharmaceutical industry with several established companies and emerging biotech companies developing new diabetes drugs. The increasing pipeline of innovative drugs provides opportunities for growth in the diabetes drugs market.

Government support: The UK government has demonstrated a commitment to investing in healthcare and promoting the use of innovative treatments. This support can create a favorable environment for pharmaceutical companies to develop and market new diabetes drugs.

Market Restraints

Cost-containment measures: The UK government has implemented cost-containment measures to manage healthcare spending, including the use of cost-effectiveness assessments by NICE. These measures can limit the availability of some newer, more expensive diabetes drugs, which may be less cost-effective in the short term.

Patent expirations: Several key diabetes drugs have lost or are expected to lose patent protection, which can lead to increased competition from generic versions of these drugs.

Stringent regulations: The UK has stringent regulations governing the approval of new drugs, which can create barriers to entry for smaller pharmaceutical companies and slow the development of new treatments.

Competitive Landscape

Key Players

  • AstraZeneca
  • GlaxoSmithKline
  • Eli Lilly and Company
  • Novo Nordisk
  • Sanofi
  • Johnson & Johnson
  • Abott
  • Bayer Pharmaceuticals
  • Merck
  • Boehringer Ingelheim
  • Novartis

Notable deals

January 2021, AstraZeneca and Provention Bio announced a collaboration to develop and commercialize a new type 1 diabetes drug called PRV-015. Under the terms of the deal, AstraZeneca made an initial payment of $100 Mn to Provention Bio, with additional milestone payments possible in the future.

April 2021, Eli Lilly and Company and Zealand Pharma announced a collaboration to develop and commercialize a new once-weekly GLP-1 analogue for the treatment of type 2 diabetes. Under the terms of the deal, Eli Lilly and Company made an upfront payment of $40 Mn to Zealand Pharma, with additional milestone payments possible in the future.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

In the UK, diabetes drugs are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA), which is responsible for ensuring the safety, efficacy, and quality of drugs in the UK. The regulatory process for diabetes drugs in the UK involves several stages, including pre-clinical studies, clinical trials, and post-marketing surveillance. The MHRA reviews drug applications and conducts inspections of manufacturing facilities to ensure compliance with Good Manufacturing Practices (GMP).

In terms of reimbursement, diabetes drugs in the UK are covered by the National Health Service (NHS), which provides free or low-cost healthcare to UK residents. Under the NHS, patients are responsible for paying a prescription fee for each medication they receive, unless they are exempt due to certain medical conditions or income levels. The cost of prescription fees is set by the government and may change from year to year.

The NHS also has a system for evaluating the cost-effectiveness of prescription drugs, known as the National Institute for Health and Care Excellence (NICE). NICE conducts assessments of new drugs and makes recommendations to the NHS on whether or not they should be funded. These assessments take into account the clinical effectiveness of the drug as well as its cost-effectiveness compared to other treatments. NICE recommendations are not binding, but they are influential in NHS funding decisions.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Diabetes Drugs Market Segmentation

By Drug Type (Revenue, USD Bn):

The drug types considered, in this report include Injectable Drugs and Oral Drugs. Injectable drugs are further classified into insulin-based and non-insulin-based injectables. Oral drugs are further classified into various classes as per their mechanism of action as mentioned below :

  • Injectable Drugs
    • Insulin Based Injectables
    • Non-insulin Based Injectables
      • Exenatide (Byetta)
      • Dulaglutide (Trulicity)
      • Semaglutide (Ozempic, Wegovy)
      • Liraglutide (`Saxenda, Victoza)
      • Lixisenatide (Adlyxin)
      • Pramlintide (Symlin)
      • Tirzepatide (Mounjaro)
      • Albiglutide (Tanzeum)
  • Oral Drugs
    • Biguanides - Metformin (Glucophage and Glucophase XR)
    • Sulfonylureas - Glimepiride (Amaryl), Glyburide (DiaBeta), Glipizide (Glucotrol), Gliclazide (Diamicron), Chlorpropamide (Diabinese)
    • Meglitinides and D-Phenylalanine Derivatives - Repaglinide (Prandin), Nateglinide (Starlix)
    • Thiazolidinediones (TZDs) - Rosiglitazone (Avandia), Pioglitazone (Actos)
    • Dipeptidyl peptidase-IV (DPP-4) inhibitors - Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta), and Alogliptin (Nesina and Vipidia), Teneligliptin (Tenelia), Vildagliptin (Galvus)
    • Alpha-glucosidase Inhibitors - Acarbose (Precose), Miglitol (Glyset), Voglibose (Voglib)
    • Sodium-glucose co-transporter-2 (SGLT2) inhibitors - Canagliflozin (Invokana), Dapagliflozin (Farxiga), Empagliflozin (Jardiance), Ertugliflozin (Stelgatro)
    • Dopamine D2 agonist – Bromocriptine (Parlodel and Cycloset)
    • Glucagon like peptide 1 (GLP-1) receptor agonists - Semaglutide (Rybelsus)
    • Bile Acid Sequestrants (BASs) - Colesevelam (Welchol)
    • Others (Fixed Dose Combination Drugs)

By Application (Revenue, USD Bn):

Based on application, the market is segmented into Type 1 and Type 2. The 2 types of diabetes drugs are segmented and dominate the market. The Type 2 diabetes segment accounts for the largest sales of the worldwide market a few different kinds. The excessive prevalence of type 2 because of sedentary lifestyles and obesity in all age groups is attributed to the current situation. Around 10% of all diabetes cases are type 1, and approximately 90% of all cases of diabetes in UK are type 2. Hence, it is estimated to the diabetes drugs market will grow across the globe during the forecast period.

  • Type 1 diabetes (due to β-cell destruction, usually leading to absolute insulin deficiency)
  • Type 2 diabetes (due to a progressive insulin secretory defect on the background of insulin resistance)
  • Other diabetes types

By Distribution Channel (Revenue, USD Bn):

Based on distribution channels, the market is classified into hospital pharmacies, rental pharmacies, and online pharmacies. The hospital pharmacies captured the highest market share, owing to the availability of trained & qualified personnel and favorable reimbursement structure. Online pharmacies are estimated to register the highest CAGR in the forecast period, it is attributed to the technological adaptation and acceptance of online pharmacies. Retail pharmacies showed a moderate market share improvement in the healthcare facilities in developing countries is anticipated to propel the popularity of retail pharmacies during the forecast period.

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 17 March 2023
Updated by: Dhruv Joshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up